

## HR 5463

### Drug Pricing Transparency and Accountability Act

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Sep 30, 2021

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Oct 1, 2021)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/5463>

## Sponsor

**Name:** Rep. Rosendale Sr., Matthew M. [R-MT-At Large]

**Party:** Republican • **State:** MT • **Chamber:** House

## Cosponsors

No cosponsors are listed for this bill.

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 1, 2021
Ways and Means Committee	House	Referred To	Sep 30, 2021

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

No related bills are listed.

## Summary (as of Sep 30, 2021)

### Drug Pricing Transparency and Accountability Act

This bill establishes a two-year moratorium on allowing new, non-rural hospitals and associated child sites to participate in the 340B drug pricing program; during the moratorium, the Department of Health and Human Services must issue regulations with specified program eligibility standards. The bill also requires additional reporting relating to program participation, eligibility, and costs.

## Actions Timeline

---

- **Oct 1, 2021:** Referred to the Subcommittee on Health.
- **Sep 30, 2021:** Introduced in House
- **Sep 30, 2021:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.